Fig. 1

Treatment Response and Survival of Patients. a Complete remission (CR) status of patients post-CAR-T infusion. Patients 1, 3, 4, 5 and 8 achieved molecular remission. Patients 2, 3, 6, 7 and 8 relapsed within four months, and Patient 1 experienced relapse at 12.2 months after the CD19 CAR-T treatment. b Schedule of the CD19 CAR-T treatment regimen. c Variation in RUNX1::RUNX1T1 fusion gene expression in the bone marrow (BM) measured by quantitative real-time PCR (RT-PCR). d CAR-T cell copy numbers were detected using vector copy numbers (VCN) analysis. e The IL-6 cytokine results during CAR-T cell treatment. f & h 12-month overall survival (OS) and leukemia-free survival (LFS) rates were 45.0% and 46.7%, respectively. h The cumulative incidence of all patients is displayed